The chart illustrates the proportion of medicine sales in a particular company in five regions from 2002 to 2006. Overall, Europe and Africa shared the largest percentage of drug revenues while the smallest went to South America. Additionally, the figure for medicine sales in Asia continually increased throughout the period.
The branch in Europe and Africa accounted for the highest percentage of the company’s drug sales with 44% in 2002, nearly half of its total revenue. The figure slightly rose by 1% in 2003 before reaching its peak of 48% in 2004, after which it began to decline in the next two years, about 4% per year. Meanwhile, Medicine sales in North America constituted the second largest proportion of the total sales in 2002, with 33%. However, the figure for drug sales in this region significantly declined by almost 10% in 2004, comprising nearly a quarter of the total sales. In 2005, North America made up approximately 20% of the total drug sales and this figure remained unchanged in 2006, placing this region third in the total sales.
Considering Asia and South America, despite sharing relatively the same percentage of drug sales in 2002, with 12% and 11% respectively, these two regions experienced a converse trend in the following years. The figure for drug sales in Asia dramatically went up to 20% in 2003 and modestly increased until 2006, when it reached its all-time high of 28%. Conversely, the proportion of medicine revenues in South America dropped by half of its initial figure in 2004, at 6%, after which it recovered to 11% and remained stable until the end of the period